Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Schedules,Therapeutic_group
"ABBVIE LIMITED, Clinician",Upadacitinib,"Ulcerative colitis, moderate to severe, 2nd line",Upadacitinib (RINVOQÂ®),Community and Hospital,Alimentary Tract and Metabolism
